Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Remicade Hepatotoxicity Warning Is Subject Of “Dear Doctor” Letter

Executive Summary

Johnson & Johnson is alerting prescribers to a new hepatotoxicity warning in Remicade labeling via a "Dear Doctor" letter

You may also be interested in...



J&J Remicade Labeling Adds TNF-Inhibitor Malignancy Warning

Centocor is revising Remicade (infliximab) labeling to include a malignancy warning similar to that of other TNF-inhibitors

J&J’s Remicade Adds Hematologic, Neurologic Warnings To Label

Johnson & Johnson's TNF-inhibitor Remicade has added warnings for hematologic and neurologic events to its label

Enbrel Cleared For Ankylosing Spondylitis; Heart Failure Precaution Added

Amgen/Wyeth is awaiting approval for two additional Enbrel indications following FDA clearance of the TNF-inhibitor for ankylosing spondylitis July 24

Related Content

Topics

UsernamePublicRestriction

Register

PS045187

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel